Mari Iwasaki1, Yasutada Akiba1,2, Jonathan D Kaunitz3,4,5. 1. West Los Angeles VAMC, 11301 Wilshire Blvd., Los Angeles, CA, 90073, USA. 2. Department of Medicine, The David Geffen School of Medicine, University of California, Los Angeles, CA, 90073, USA. 3. West Los Angeles VAMC, 11301 Wilshire Blvd., Los Angeles, CA, 90073, USA. jake@ucla.edu. 4. Department of Medicine, The David Geffen School of Medicine, University of California, Los Angeles, CA, 90073, USA. jake@ucla.edu. 5. Department of Surgery, The David Geffen School of Medicine, University of California, Los Angeles, CA, 90073, USA. jake@ucla.edu.
Abstract
PURPOSE OF REVIEW: Short-chain fatty acids (SCFAs), the main bacterial fermentation products in the hindgut of hindgut fermenters, are also present in the foregut lumen. We discuss the impact of SCFAs in the duodenal defense mechanisms and in the gastrointestinal (GI) pathogenesis. RECENT FINDINGS: Luminal SCFAs augment the duodenal mucosal defenses via release of serotonin (5-HT) and glucagon-like peptide-2 (GLP-2) from enteroendocrine cells. Released GLP-2 protects the small intestinal mucosa from nonsteroidal anti-inflammatory drug-induced enteropathy. SCFAs are also rapidly absorbed via SCFA transporters and interact with afferent and myenteric nerves. Excessive SCFA signals with 5-HT3 receptor overactivation may be implicated in the pathogenesis of irritable bowel syndrome symptoms. SCFA production exhibits diurnal rhythms with host physiological responses, suggesting that oral SCFA treatment may adjust the GI clocks. SCFAs are not only a source of energy but also signaling molecules for the local regulation of the GI tract and systemic regulation via release of gut hormones. Targeting SCFA signals may be a novel therapeutic for GI diseases and metabolic syndrome.
PURPOSE OF REVIEW: Short-chain fatty acids (SCFAs), the main bacterial fermentation products in the hindgut of hindgut fermenters, are also present in the foregut lumen. We discuss the impact of SCFAs in the duodenal defense mechanisms and in the gastrointestinal (GI) pathogenesis. RECENT FINDINGS:LuminalSCFAs augment the duodenal mucosal defenses via release of serotonin (5-HT) and glucagon-like peptide-2 (GLP-2) from enteroendocrine cells. Released GLP-2 protects the small intestinal mucosa from nonsteroidal anti-inflammatory drug-induced enteropathy. SCFAs are also rapidly absorbed via SCFA transporters and interact with afferent and myenteric nerves. Excessive SCFA signals with 5-HT3 receptor overactivation may be implicated in the pathogenesis of irritable bowel syndrome symptoms. SCFA production exhibits diurnal rhythms with host physiological responses, suggesting that oral SCFA treatment may adjust the GI clocks. SCFAs are not only a source of energy but also signaling molecules for the local regulation of the GI tract and systemic regulation via release of gut hormones. Targeting SCFA signals may be a novel therapeutic for GI diseases and metabolic syndrome.
Authors: Xinfu Guan; Heidi E Karpen; John Stephens; John T Bukowski; Sanyong Niu; Guangcheng Zhang; Barbara Stoll; Milton J Finegold; Jens J Holst; Darryl Hadsell; Darry L Hadsell; Buford L Nichols; Douglas G Burrin Journal: Gastroenterology Date: 2006-01 Impact factor: 22.682
Authors: Luis Alberto Bravo-Vázquez; Ixchel Medina-Ríos; Luis David Márquez-Gallardo; Josué Reyes-Muñoz; Francisco I Serrano-Cano; Surajit Pathak; Antara Banerjee; Anindya Bandyopadhyay; Asim K Duttaroy; Sujay Paul Journal: Dig Dis Sci Date: 2022-05-04 Impact factor: 3.487
Authors: Seppo Salminen; Maria Carmen Collado; Akihito Endo; Colin Hill; Sarah Lebeer; Eamonn M M Quigley; Mary Ellen Sanders; Raanan Shamir; Jonathan R Swann; Hania Szajewska; Gabriel Vinderola Journal: Nat Rev Gastroenterol Hepatol Date: 2021-05-04 Impact factor: 73.082